Annual PHA Educational Forum For Pulmonary Hypertension Awareness Reaches Texas and California in September
The Pulmonary Hypertension Association (PHA) is organizing another edition of the annual educational forum “PHA On the Road,” intended to provide support to not only patients and families living with pulmonary hypertension (PH), but also medical professionals. Houston, Texas and San Diego, California are the two locations where the event will be held, which is taking place in September.
PHA On the Road is a free full-day regional education forum organized in line with PHA’s mission to prevent and cure PH, as they believe that they can provide the community with hope by supporting education, research, advocacy, and awareness for fighting the disease. The association expects, therefore, to connect with the PH community, including patients, families, physicians, and caregivers.
The Texas events will take place on Saturday, September 6th, at the Westin Houston in Memorial City. In California, the event is planned for Saturday, September 20 at the Westin San Diego. Both conferences will happen between 8:30 a.m. and 4:30 p.m. The event aims to reach the PH community close to their homes, targeting people who are not able to travel to participate in the PHA’s Biennial International Conference and Scientific Sessions.
According to the association, it “delivers much needed PH education and support to patients and families in areas close to home. The forums feature interactive presentations, education sessions and networking opportunities with other patients, caregivers and medical professionals.”
Confirmed speakers at the educational forum in Houston include Shervin Assassi, MD, MS, from The University of Texas Medical School at Houston, Alexander Duarte, MD, from the University of Texas Medical Branch, as well as Monica Esquivel, BSN, RN, MSN, ACNPC, from the University of Texas Health Science Center at San Antonio, among many others.
Pulmonary hypertension is a disease of the lungs that affects the normal function of the heart, which can lead right to heart failure and registers a survivability rate of 2.8 years, if not treated.